In addition, AGR2 has been reported to be released into the circu

In addition, AGR2 has been reported to be released into the circulation of ovarian cancer patients [11]. Previous studies have reported that overexpression of AGR2 may promote BTSA1 chemical structure the development of metastatic phenotype in benign breast cancer cell [42] and secreted AGR2 has been implicated in promoting proliferation of pancreatic cell lines in culture [44]. In addition, circulating tumor cells from patients with advanced metastatic disease display elevated AGR2 gene expression [45] suggesting that AGR2 may play a

functional role in Rapamycin research buy metastasis or may represent a useful biomarker of circulating tumor cells [46]. Conclusion The data obtained in this study confirm that the measurement of plasma concentrations of MDK and AGR2 Ulixertinib supplier individually display utility as biomarkers for ovarian cancer and that when included in a multi-analyte panel may significantly improve the diagnostic utility of CA125 in symptomatic women. Acknowledgements GER is in receipt of an NHMRC Principal Research Fellowship. The study was funded as part of the research and development operations of Healthlinx Ltd. References 1. Paley PJ: Ovarian cancer screening: are we making any progress? Curr Opin Oncol 2001, 13:399–402.PubMedCrossRef 2. Nossov V, Amneus

M, Su F, Lang J, Janco JMT, Reddy ST, Farias-Eisner R: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics and Gynecology 2008, 199:215–223.PubMedCrossRef 3. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Molecular & Cellular Proteomics 2004, 3:355–366.CrossRef 4. Lokshin AE, Yurkovetsky Z, Bast R, Lomakin A, Maxwel GL, Godwin AK: Serum multimarker assay for early diagnosis of ovarian cancer. Gynecologic Oncology 2008,

108:S113-S114. 5. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC: Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention 2008, 17:2872–2881.CrossRef triclocarban 6. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R: Validation of serum biomarkers for detection of early-stage ovarian cancer. American Journal of Obstetrics and Gynecology 2009, 200. 7. Zhang Z, Bast RC, Vergote I, Hogdall C, Ueland FR, Van der Zee A, Wang Z, Yip C, Chan DW, Fung ET: A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. Journal of Clinical Oncology 2006, 24:269S-269S. 8. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE: Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncology 2010. 9.

Comments are closed.